Differentiation Syndrome in the Era of Targeted Therapies for Acute Myeloid Leukemia

Differentiation syndrome (DS) has re-emerged as a clinically significant toxicity with the advent of molecularly targeted therapies in AML. Once primarily associated with APL, DS is now observed with agents that induce leukemic differentiation. As these therapies are increasingly used in earlier lines and combination regimens, clinicians must recognize DS as an on-target toxicity with variable timing, risk factors, and clinical manifestations. Dr. Tiffany Tanaka, of UC San Diego Health, notes, “With newer agents, DS can develop gradually, often in the outpatient setting, and may arise weeks to months into therapy, easily confused with other AML complications.”

At a mechanistic level, DS results from rapid maturation of leukemic blasts into functional myeloid cells, triggering cytokine release, endothelial activation, capillary leak, and tissue infiltration. Clinically, this presents as fever, dyspnea, hypoxia, pulmonary infiltrates or effusions, weight gain, hypotension, renal dysfunction, and leukocytosis. Diagnosis remains clinical and one of exclusion, requiring vigilance, particularly early in therapy or during brisk hematologic responses.

Differentiation Syndrome in Menin Inhibitors

Menin inhibitors disrupt the interaction between menin and KMT2A (MLL), restoring differentiation in leukemias with KMT2A rearrangements or NPM1 mutations. Dr. Tanaka explains “differentiation syndrome is when you have the immature myeloid cells actually differentiating with the treatment, and that causes a lot of systemic inflammation.”

Revumenib was the first FDA‑approved menin inhibitor. In the phase I/II AUGMENT‑101 trial, DS occurred in approximately 19% of patients receiving revumenib monotherapy, often emerging early, as soon as 3 days, with most cases occurring within six weeks. The median time to onset was 10 days. Management included corticosteroids and occasional drug interruption. In the BEAT AML Master Trial combining revumenib with azacitidine and venetoclax in newly diagnosed older patients with NPM1 or KMT2A alterations, DS was reported in about 19% of patients amid high overall response rates exceeding 85% and frequent deep molecular remissions. Real‑world and follow‑up data continue to emphasize that the strength of differentiation response often parallels DS risk, underscoring the need for vigilant monitoring during rapid hematologic responses.

Ziftomenib is the second menin inhibitor recently approved for relapsed or refractory NPM1‑mutated AML. In the pivotal KOMET‑001 trial in 112 patients with NPM1‑mutated disease treated at the recommended 600 mg daily dose, DS occurred in around 26% of patients, with grade 3 events in 13% and two fatal cases reported; onset ranged from as early as 3 days to about 46 days, with a median of 15 days after initiation.

DS was seen with and without hyperleukocytosis, and management included treatment interruption and corticosteroids, with rechallenge after improvement in some patients. Broader analyses in all ziftomenib‑treated AML patients across trials show a similar DS incidence (~25%), including a higher rate in patients with KMT2A rearrangements with several fatal events in this subgroup, though ziftomenib is not currently approved for KMT2A‑rearranged AML. Ziftomenib’s overall response rates in relapsed/refractory NPM1‑mutated AML are reported as 33%, with median survival outcomes consistent with meaningful clinical benefit.

Across menin inhibitors, DS reflects successful on‑target differentiation but mandates standardized monitoring and early intervention. Trial protocols and prescribing information now emphasize early recognition and steroid initiation, reflecting lessons from earlier IDH inhibitor experience. Menin inhibitors also carry other safety signals: revumenib notably QTc prolongation further reinforcing comprehensive surveillance during therapy.

Differentiation Syndrome Beyond Menin Inhibitors

DS is well characterized with IDH inhibitors. Therapies such as ivosidenib (IDH1), enasidenib (IDH2), and olutasidenib (next‑generation IDH1) reverse differentiation blocks and cause DS as a class effect. Pooled analyses have identified DS in 19% of patients treated with ivosidenib or enasidenib, often accompanied by leukocytosis and occurring days to months into therapy. Olutasidenib’s clinical data show DS in approximately 16% of patients, with grade 3/4 events in 8% and rare fatalities.

While less common, differentiation phenomena and DS have also been reported with FLT3 inhibitors such as gilteritinib, with incidence around 3% in clinical settings. These events underscore the need for clinical awareness when new pulmonary symptoms or leukocytosis arise during therapy.

DS remains a clinical diagnosis requiring exclusion of infection, cardiopulmonary etiologies, and leukostasis; high‑dose corticosteroids should be initiated promptly upon suspicion. Supportive care, including oxygen and hemodynamic support, is essential. Temporary interruption of offending agent is recommended for severe or refractory cases, with aggressive cytoreduction for marked leukocytosis. Most patients recover fully with timely intervention, though recurrence may occur with premature steroid tapering. Dr. Tanaka explains “a lot of us are used to seeing DS in the setting of APL during induction therapy, and that happens rapidly when those patients are in the hospital… [targeted therapy] DS can happen a lot more gradually. It happens as an outpatient, so it’s on the patient themselves to recognize it and act on it and go to the ER.”

Differentiation syndrome has evolved from a niche APL toxicity into a central safety consideration across targeted AML therapies. Menin inhibitors carry a measurable DS risk tied to potent differentiation effects, and clinicians must integrate early diagnosis and intervention into routine care to maximize therapeutic benefit while minimizing morbidity and mortality.